US Congress still has questions on Vytorin cancer report
This article was originally published in Scrip
Executive Summary
Two US House of Representatives Democrats have raised more questions about documents relating to the SEAS trial on Merck/Schering-Plough's Vytorin (ezetimibe plus simvastatin).The trial recently turned up an unexpected link to cancer and cancer-related deaths. The Democrats are seeking an answer as to whether an esteemed scientific consultant generated a secret report to the USFDA. The expanded probe comes as researchers at the European Society of Cardiology in Munich released fuller data from the SEAS trial.